Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 9/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 5/20 | 0.39 |
| ▸ | CYP2E1 | P05181 | 3/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | LPL | P06858 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | PTPRC | P08575 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6320052 | 0.82 | CYP2A6 (0.52) | CYP2A6CYP2B6CYP2E1MAPTGPR35 | |
| SCHEMBL2094304 | 0.81 | CYP2A6 (0.50) | CYP2A6CYP2B6CYP2E1BTKLPL | |
| SCHEMBL14003393 | 0.79 | CYP2A6 (0.53) | CYP2A6CYP2B6CYP2E1BTKGPR35 | |
| SCHEMBL28179635 | 0.76 | CYP2A6 (0.42) | CYP2A6CYP2B6CYP2E1BTKMAPT | |
| SCHEMBL14987844 | 0.76 | PDGFRB (0.45) | CYP2A6CYP2B6CYP2E1BTKGPR35 | |
| SCHEMBL28180442 | 0.76 | CYP2A6 (0.43) | CYP2A6CYP2B6CYP2E1BTKGPR35 | |
| SCHEMBL21848864 | 0.74 | CYP2A6 (0.59) | CYP2A6CYP2B6CYP2E1LPLLIPG | |
| SCHEMBL10767146 | 0.74 | CYP2A6 (0.49) | CYP2A6CYP2B6CYP2E1BTKMEN1 | |
| SCHEMBL9646101 | 0.73 | CYP2A6 (0.43) | CYP2A6CYP2B6CYP2E1LPLLIPG | |
| SCHEMBL14506751 | 0.73 | KCNH2 (0.53) | CYP2A6CYP2B6CYP2E1LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4281456-A1 | NOVEL BICYCLIC COMPOUNDS | PRISM BioLab Co., Ltd. (JP) | 2023-11-29 | — | — | EP | disclosed |
| US-20230374034-A1 | NOVEL BICYCLIC COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2023-11-23 | — | — | US | disclosed |
| WO-2023200017-A1 | NOVEL SEVEN-MEMBERED RING-FUSED COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2023-10-19 | — | — | WO | disclosed |
| CN-116710455-A | Novel bicyclic compounds | 株式会社棱镜生物实验室 | 2023-09-05 | — | — | CN | disclosed |
| US-20230265104-A1 | NOVEL HETEROCYCLIC COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2023-08-24 | — | — | US | disclosed |
| EP-4225760-A1 | NOVEL BICYCLIC COMPOUNDS | PRISM BioLab Co., Ltd. (JP) | 2023-08-16 | — | — | EP | disclosed |
| CN-116348119-A | Novel bicyclic compounds | 株式会社棱镜生物实验室 | 2023-06-27 | — | — | CN | disclosed |
| EP-4182317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PRISM BioLab Co., Ltd. (JP) | 2023-05-24 | — | — | EP | disclosed |
| CN-116018345-A | Novel heterocyclic compounds | 株式会社棱镜生物实验室 | 2023-04-25 | — | — | CN | disclosed |
| WO-2022075486-A1 | NOVEL BICYCLIC COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2022-04-14 | — | — | WO | disclosed |
| US-7473694-B2 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2009-01-06 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1864986-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-07-26 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-6040449-A | USEFUL FOR FORMING FLUORINE CONTAINING 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES, USEFUL AS ANTAGONIST FOR MUSCARINIC M3 RECEPTORS AND LESS SIDE EFFECT | BANYU PHARMACEUTICAL CO LTD (JP) | 2000-03-21 | — | — | US | disclosed |
| US-5948792-A | POTENT AND SELECTIVE ANTAGONISTS FOR MUSCARINIC M.SUB.3 RECEPTORS WITH LITTLE SIDE EFFECTS. | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0930298-A1 | FLUORINATED 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374034-A1 | NOVEL BICYCLIC COMPOUNDS | NOTCH1, NOTCH2, HES1 | CYP2A6 3870/4885CYP2B6 3331/4885CYP2E1 2771/4885 |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAPKAPK5, MAPKAPK3 | CYP2A6 3496/4885CYP2B6 4155/4885CYP2E1 4392/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | CYP2A6 1153/4885CYP2B6 714/4885CYP2E1 1365/4885 |
| US-20230265104-A1 | NOVEL HETEROCYCLIC COMPOUNDS | MKI67, CCNI, KRAS | CYP2A6 3211/4885CYP2B6 2157/4885CYP2E1 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.